Figure 6.

QPCTL deficiency sensitizes the tumor microenvironment to anti-PD-L1 treatment. QPCTL^+/+ and QPCTL^−/− mice were inoculated with QPCTL-WT and QPCTL-KO B16F10 melanoma cells, respectively. Each group subsequently received either anti-PD-L1 or isotype control antibody treatment at day 7, 9 and 11 post tumor inoculation. (a) Tumor growth curves, assessed until day 50 post tumor inoculation. Lines represent individual mice. Data from two experiments are depicted (n = 5 per group). (a) Survival probabilities of mice treated with anti-PD-L1 or isotype control antibody in a QPCTL-proficient and -deficient setting. Black plus-signs indicate censored events. Data from two experiments are depicted (n = 5 per group). Global P values were determined by log-rank test (b). Data from 2 independent experiments are depicted.